Compare CMCO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | CAPR |
|---|---|---|
| Founded | 1875 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.6M | 584.9M |
| IPO Year | 2002 | 2011 |
| Metric | CMCO | CAPR |
|---|---|---|
| Price | $15.75 | $9.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $21.00 | ★ $44.63 |
| AVG Volume (30 Days) | 345.2K | ★ 5.9M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $936,240,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $82.91 | $3.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.27 | N/A |
| 52 Week Low | $11.99 | $2.96 |
| 52 Week High | $24.40 | $40.37 |
| Indicator | CMCO | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 48.78 |
| Support Level | $14.62 | $8.18 |
| Resistance Level | $16.42 | $11.00 |
| Average True Range (ATR) | 0.73 | 0.69 |
| MACD | -0.31 | 0.22 |
| Stochastic Oscillator | 4.97 | 29.57 |
Columbus McKinnon Corp is a world-wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Its key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements. The company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.